These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 21796541)

  • 1. Levodopa medication does not influence motor inhibition or conflict resolution in a conditional stop-signal task in Parkinson's disease.
    Obeso I; Wilkinson L; Jahanshahi M
    Exp Brain Res; 2011 Sep; 213(4):435-45. PubMed ID: 21796541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The motor inhibition system in Parkinson's disease with levodopa-induced dyskinesias.
    Cerasa A; Donzuso G; Morelli M; Mangone G; Salsone M; Passamonti L; Augimeri A; Arabia G; Quattrone A
    Mov Disord; 2015 Dec; 30(14):1912-20. PubMed ID: 26275050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa improves response inhibition and enhances striatal activation in early-stage Parkinson's disease.
    Manza P; Schwartz G; Masson M; Kann S; Volkow ND; Li CR; Leung HC
    Neurobiol Aging; 2018 Jun; 66():12-22. PubMed ID: 29501966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.
    Picazio S; Ponzo V; Caltagirone C; Brusa L; Koch G
    J Neurol; 2018 Sep; 265(9):2088-2096. PubMed ID: 29980853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors.
    Claassen DO; van den Wildenberg WP; Harrison MB; van Wouwe NC; Kanoff K; Neimat JS; Wylie SA
    Pharmacol Biochem Behav; 2015 Feb; 129():19-25. PubMed ID: 25459105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa medication improves incidental sequence learning in Parkinson's disease.
    Beigi M; Wilkinson L; Gobet F; Parton A; Jahanshahi M
    Neuropsychologia; 2016 Dec; 93(Pt A):53-60. PubMed ID: 27686948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.
    Hanna-Pladdy B; Pahwa R; Lyons KE
    J Int Neuropsychol Soc; 2015 Apr; 21(4):259-70. PubMed ID: 25923830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain dopaminergic modulation associated with executive function in Parkinson's disease.
    Farid K; Sibon I; Guehl D; Cuny E; Burbaud P; Allard M
    Mov Disord; 2009 Oct; 24(13):1962-9. PubMed ID: 19672989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic influences on the P300 abnormality in Parkinson's disease.
    Sohn YH; Kim GW; Huh K; Kim JS
    J Neurol Sci; 1998 Jun; 158(1):83-7. PubMed ID: 9667783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-band oscillations in the supplementary motor cortex are modulated by levodopa and associated with functional activity in the basal ganglia.
    Chung JW; Burciu RG; Ofori E; Coombes SA; Christou EA; Okun MS; Hess CW; Vaillancourt DE
    Neuroimage Clin; 2018; 19():559-571. PubMed ID: 29984164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease.
    Martinu K; Degroot C; Madjar C; Strafella AP; Monchi O
    Eur J Neurosci; 2012 Feb; 35(4):572-83. PubMed ID: 22304628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa and the feedback process on set-shifting in Parkinson's disease.
    Au WL; Zhou J; Palmes P; Sitoh YY; Tan LC; Rajapakse JC
    Hum Brain Mapp; 2012 Jan; 33(1):27-39. PubMed ID: 21438075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal study of the levodopa motor response in Parkinson's disease: relationship between cognitive decline and motor function.
    Alty JE; Clissold BG; McColl CD; Reardon KA; Shiff M; Kempster PA
    Mov Disord; 2009 Dec; 24(16):2337-43. PubMed ID: 19890972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study.
    Rinaldi D; Assogna F; Sforza M; Tagliente S; Pontieri FE
    Neurol Sci; 2018 Jan; 39(1):141-143. PubMed ID: 28956175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J; Rodríguez-Oroz MC
    Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The single intake of levodopa modulates implicit learning in drug naïve, de novo patients with idiopathic Parkinson's disease.
    Geffe S; Schindlbeck KA; Mehl A; Jende J; Klostermann F; Marzinzik F
    J Neural Transm (Vienna); 2016 Jun; 123(6):601-10. PubMed ID: 27106907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa slows prosaccades and improves antisaccades: an eye movement study in Parkinson's disease.
    Hood AJ; Amador SC; Cain AE; Briand KA; Al-Refai AH; Schiess MC; Sereno AB
    J Neurol Neurosurg Psychiatry; 2007 Jun; 78(6):565-70. PubMed ID: 17178817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa Effect on Basal Ganglia Motor Circuit in Parkinson's Disease.
    Gao LL; Zhang JR; Chan P; Wu T
    CNS Neurosci Ther; 2017 Jan; 23(1):76-86. PubMed ID: 27663605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age at Parkinson's disease onset modulates the effect of levodopa on response inhibition: Support for the dopamine overdose hypothesis from the antisaccade task.
    Waldthaler J; Stock L; Krüger-Zechlin C; Timmermann L
    Neuropsychologia; 2021 Dec; 163():108082. PubMed ID: 34728241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic Effect on Non-Motor Symptoms in Late Stage Parkinson's Disease.
    Rosqvist K; Odin P; Hagell P; Iwarsson S; Nilsson MH; Storch A
    J Parkinsons Dis; 2018; 8(3):409-420. PubMed ID: 30056433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.